Affitech Signs Antibody Development Agreement With Omeros
Affitech and Omeros have signed an agreement for the discovery and development of fully human antibodies for Omeros’s MASP-2 program.
MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway and is linked to multiple potential indications across a wide range of inflammatory diseases including macular degeneration, rheumatoid arthritis, transplant rejection and cardiovascular and renal ischemia-reperfusion injury.
Under this collaboration, Omeros, based on its exclusive intellectual property position, will continue to advance the development of its MASP-2 program. Affitech will apply its expansive human antibody libraries and proprietary antibody discovery and screening technologies, including its AffiScreen platform and engineering methods, to generate fully human MASP-2 antibodies for Omeros.
Financial terms include a technology access fee, a series of milestone payments, and royalties on net sales, payable by Omeros.
Gregory Demopulos, chairman and CEO of Omeros, said: “This agreement marks an important milestone in our MASP-2 program, and ensures that Omeros can access high-affinity, fully human antibodies against MASP-2. We are impressed by Affitech’s technology, track record and personnel, and look forward to our collaboration.”